The companies came under intense scrutiny in January 2008 after they released a study — completed nearly two years earlier — that showed that the medicines, the work of a joint venture, were no more effective in unclogging arteries than a pre-existing and less expensive cholesterol treatment.
Thursday, August 06, 2009
Merck Schering-Plough - Vytorin: the $ettlement
Merck and Schering-Plough agreed Wednesday to pay $41.5 million to settle class-action lawsuits that accused them of withholding unfavorable results of a clinical trial of the cholesterol drugs Vytorin and Zetia.
The companies came under intense scrutiny in January 2008 after they released a study — completed nearly two years earlier — that showed that the medicines, the work of a joint venture, were no more effective in unclogging arteries than a pre-existing and less expensive cholesterol treatment.
A U.S. Department of Justice investigation is still pending, as are lawsuits alleging securities-law violations.
The companies came under intense scrutiny in January 2008 after they released a study — completed nearly two years earlier — that showed that the medicines, the work of a joint venture, were no more effective in unclogging arteries than a pre-existing and less expensive cholesterol treatment.
Subscribe to:
Post Comments (Atom)
1 comment:
For your information, Paul Janssen was Belgian and not Dutch. The company he founded, now part of J&J still operates in Beerse (Belgium) close to his birth place.
Post a Comment